Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session
CHENGDU, China, Sept. 22, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Multiple Phase III clinical studies of the TROP2 ADC sacituzumab tirumotecan...
TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection
— Phase IIb multicenter trial initiated, bringing this potential life-changing therapy closer to patients — SUZHOU, China, Sept. 10, 2026 /PRNewswire/ -- TenNor Therapeutics, a near-commercial-stage biotechnology company, today announced positive...
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data...
Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada. -Positive preclinical data in...
SHIMENG Supply Chain Management Launches A-Share IPO, Largest External Shareholder Shoucheng Holdings (0697.HK) Sees Investment Value Enter Realization Phase
HONG KONG, Jan. 19, 2026 /PRNewswire/ -- SHIMENG SUPPLY CHAIN MANAGEMENT CO., LTD. ("SHIMENG"), an investee company of Shoucheng Holdings (0697.HK), has recently initiated its initial public offering (IPO) process on the Main Board of the Shenzhen...
BioDlink's Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion
BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil (a PIC/S member), Colombia, Egypt, Indonesia, and...